Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Friday, November 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

SmartLab Exchange Europe 2027 Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 3

ProBio and AbTis Partner to Develop Next-Generation Cancer ADC

Nov 12, 2026
ProBio has entered into an exclusive global licensing agreement with South Korean biotechnology company AbTis to develop a new antibody-drug conjugate (ADC) for cancer treatment. The…
Read More...

Moderna Reports 29% Revenue Growth in Third Quarter 2026

Nov 12, 2026
Moderna has reported a 29% increase in revenue for the third quarter of 2026, supported by stronger international sales of its COVID-19 vaccine and progress in its cancer vaccine…
Read More...

AstraZeneca Acquires Omniose to Strengthen Bacterial Vaccine Research

Nov 12, 2026
AstraZeneca has acquired Omniose, a US-based preclinical biotechnology company developing vaccines against serious bacterial infections. The acquisition will strengthen AstraZeneca's…
Read More...

Shanton Pharma Secures EMA and FDA Waivers for SAP-001

Nov 12, 2026
Shanton Pharma has received regulatory waivers from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), removing the need for additional pediatric…
Read More...

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

Nov 10, 2026
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Johnson & Johnson's (J&J) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for adults with…
Read More...

Network Bio and Duke Partner to Build AI Models of Human Disease

Nov 10, 2026
Biotechnology company Network Bio has announced a research collaboration with Duke University to develop artificial intelligence (AI) models that could improve disease detection,…
Read More...

Alfasigma Wins EU Approval for Filgotinib in Axial Spondyloarthritis

Nov 6, 2026
Alfasigma has received European Commission approval to expand the use of filgotinib for adults with active axial spondyloarthritis (axSpA), a chronic inflammatory disease that mainly…
Read More...

Boehringer Ingelheim Signs $7B Oncology Deal with SBP Group

Nov 6, 2026
Boehringer Ingelheim has entered into a major oncology partnership with China's Sino Biopharmaceutical Limited (SBP Group) to develop next-generation cancer treatments using…
Read More...

Evommune Licenses Hinova’s EVO570 in $1.1B Deal for Autoimmune Diseases

Nov 6, 2026
Evommune, Inc. has entered into an exclusive licensing agreement with China's Hinova Pharmaceuticals to develop and commercialise EVO570, an experimental oral drug designed to treat…
Read More...

T-Therapeutics Raises $133M to Advance Cancer and Autoimmune Therapies

Nov 6, 2026
T-Therapeutics, a biotechnology company based in Cambridge, UK, has raised $133 million in an oversubscribed Series B financing round to advance its experimental treatments for cancer…
Read More...
Previous 1 2 3 4 5 … 966 Next
Oligonucleotide-based Therapeutics Summit
LEAP HR: Life Sciences Europe
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Antigen-Specific Immune Tolerance Summit
7th Operationalize Expanded Access Programs Summit
Viral Vector Process Development & Manufacturing Summit
SmartLab Exchange Europe 2027
8th RNAi-Based Therapeutics Summit
17th World ADC London
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • OBI Pharma Signs $2 Billion ADC Deal with Novartis
  • Erasca and Bristol Myers Squibb Partner on Pancreatic Cancer Treatment
  • GSK Wins FDA Approval for Nelkarmi in Advanced Lung Cancer
  • OXB Partners with Aura Biosciences for Phase 3 Cancer Drug Development
  • Skylark Bio Advances Hearing Loss Gene Therapy to Younger Children

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Cell Therapy Safety in Autoimmune Disease

7th Operationalize: Expanded Access Programs Summit East…

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.